Loading organizations...
§ Private Profile · Horw, Luzern, Switzerland
Medical device company developing wearable insulin delivery devices for type 2 diabetes patients, focused on injection-free bolus dosing.
CeQur, based in Horw, Switzerland, with additional operations in Marlborough, Massachusetts, and Nordborg, Denmark, develops and commercializes wearable, injection-free insulin delivery devices designed to manage type 2 diabetes. The company's flagship FDA-cleared and CE-marked patch, Simplicity, provides bolus insulin dosing for up to four days and is currently utilized by over 6,000 patients following its initial pilot launch across top United States diabetes centers. To support manufacturing scale-up and commercial sales expansion, the medical technology firm has secured significant capital, including a $115 million round in April 2021 and an additional $120 million financing in 2023. The organization is backed by institutional investors such as GMS Capital Partners and Arthurian Life Sciences, while its executive leadership includes CEO Bradley Paddock, Executive Chairman Eric Milledge, and former executive Robert Farra. CeQur was established in January 2008.
CeQur Simplicity has raised $252.0M across 4 funding rounds.
CeQur Simplicity has raised $252.0M in total across 4 funding rounds.
CeQur Simplicity has raised $252.0M in total across 4 funding rounds.
CeQur Simplicity's investors include Credit Suisse, Endeavour Vision, Federated Kaufmann Fund, GMS Capital Partners, Kingdon Capital, Schroders, John F. Sheridan, VI Partners, Ypsomed Group, Arthurian Life Sciences, Woodford Investment Management, BMC Ventures.
CeQur Simplicity has raised $252.0M across 4 funding rounds. Most recently, it raised $115.0M Other Equity in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 13, 2021 | $115M Venture Round | Credit Suisse, Endeavour Vision | Federated Kaufmann Fund, GMS Capital Partners, Kingdon Capital, Schroders, John F. Sheridan, VI Partners, Ypsomed Group | Announced |
| Sep 1, 2015 | $100M Series C | Arthurian Life Sciences, Woodford Investment Management | Endeavour Vision, Schroders, VI Partners | Announced |
| Sep 9, 2013 | $27M Series B | — | — | Announced |
| Jan 5, 2010 | $10M Series A | — | BMC Ventures, Endeavour Vision, Schroders, Venture Incubator | Announced |